

Autumn Meeting MolecularDiagnostics.be

December 10th 2024, 12h45 – 17h

BIP ('huis van het gewest')

Koningsstraat 2-4, Brussels, Belgium

12:45 Registration and Coffee

13:00 Welcome

Friedel Nollet, President MD.be

Parallel session – Microbiology

Chairs: Merijn Vanhee & Dagmar Obbels

13:30 A multicenter evaluation of the QIAstat-Dx meningitis-encephalitis syndromic test kit as compared to the conventional diagnostic microbiology workflow

Robin van Houdt, UMC Amsterdam

14:00 Influence of extraction methods on 16S nanopore sequencing results

Florence Crombé & Hannelore Hamerlinck on behalf of the MD.be NGS microbiology working group

14:30 Sensitive screening of TORCH viromes on low-pass whole genome sequencing data from first-pass NIPT: clinical actionability

Geert Martens & Koen Swaerts, AZ Delta Roeselare

14:50 Break

15:45 Seek and you will find: detection of Escherichia albertii in a routine clinical microbiology lab

Klaartje De Rauw, AZ Sint-Lucas Gent

16:00 Molecular biologist's (gastro-intestinal) discomfort due to false positive testing (Norovirus)

Jitse Broos, Imelda Bonheiden

16:15 A quantitative 16S rRNA sequencing approach to detect (fastidious) bacterial species in clinical samples.

Jozef Dingemans, Jessa ziekenhuis Hasselt

16:30 Pathogen-agnostic methods for virus surveillance and diagnostics

Mustafa Karatas, UZ Leuven

Parallel session – Hematology and Pathology

Chairs: Guy Froyen & Elke Boone

13:30 Flow versus molecular MRD in AML

Barbara Depreter, AZ Delta Roeselare

14:00 Challenges and Pitfalls in Molecular MRD Detection: an overview

Marleen Bakkus, UZ Brussel

14:30 Optimization of 'limited' samples for MRD analysis

Sabine Franke, CHU de Liège

14:50 Break

15:45 Determination of measurement uncertainty of the BCR::ABL1 p210 real-time PCR analysis

Friedel Nollet, AZ Sint-Jan Brugge

16:05 Feasibility of a tumor-agnostic MRD detection approach with the Avida Methyl assay for adjuvant treatment de-escalation in early-stage colorectal cancer

Sarah Deville, Jessa ziekenhuis Hasselt

16:25 Challenges in Monitoring Patients with Rare Fusions in Hematological Malignancies. How Far to Go in Validation?

Barbara Dewaele, KU Leuven

16:45 Short brainstorm on minimal validation criteria for MRD analysis

17:00 The End